The International Journal of Surgical Oncology, published by HINDAWI LTD, stands as a pivotal resource within the realms of surgical and oncology research, with a commendable impact on the field since its inception. Established as an Open Access journal in 2010, it facilitates the dissemination of high-quality, peer-reviewed research that is accessible to a global audience, ensuring that the latest advancements in surgical techniques and oncology treatments reach researchers, practitioners, and students alike. With its current standings of Q3 in Oncology and Q2 in Surgery, alongside impressive Scopus rankings—150/551 in Medicine _ Surgery and 224/404 in Medicine _ Oncology—the journal is recognized for its influential contributions to these critical medical fields. Covering a wide array of topics from innovative surgical methods to comprehensive cancer care approaches, the journal aims to foster collaboration and knowledge-sharing among professionals seeking to enhance patient outcomes across diverse surgical oncology practices. With continued convergence of research from 2012 to 2024, the journal remains at the forefront of addressing contemporary challenges faced in surgical oncology today.

Welcome to JCO Clinical Cancer Informatics, an esteemed journal at the forefront of the intersection between oncology and health informatics. Published by Lippincott Williams & Wilkins, this journal is dedicated to advancing the understanding and application of cancer data through innovative informatics solutions. Since its inception in 2017, JCO Clinical Cancer Informatics has established itself as a critical resource for researchers, practitioners, and students, as evidenced by its high rankings in the 2023 Scimago Quartiles—Q2 in Cancer Research and Q1 in both Health Informatics and Oncology. With a commitment to open access, this journal aims to disseminate groundbreaking research findings that enhance cancer care and inform public health strategies. Positioned in the United States, it serves as a pivotal platform for sharing knowledge and fostering collaboration within the global cancer research community.

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

npj Breast Cancer, published by NATURE PORTFOLIO, stands at the forefront of breast cancer research as an esteemed open access journal since 2015. With its impressive trajectory, the journal has garnered a notable impact within the academic community, reflecting a Q1 ranking in prestigious categories such as Oncology, Pharmacology, and Radiology for 2023. Based in the United Kingdom and indexed under E-ISSN 2374-4677, npj Breast Cancer aims to disseminate cutting-edge research that fosters innovation in prevention, diagnosis, and treatment of breast cancer, thereby addressing one of the most pressing health issues of our time. Its placement within Scopus rankings, including a remarkable 19th position in Pharmacology and a percentile ranking in the 90th range for Radiology and Oncology, highlights its significance as a key resource for researchers, healthcare professionals, and policy-makers dedicated to advancing cancer care. Emphasizing accessibility and high-quality content, npj Breast Cancer provides an influential platform for interdisciplinary collaboration and discovery in the ongoing battle against breast cancer.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Pancreatology is a prestigious journal published by ELSEVIER, focusing on the multifaceted disciplines of endocrinology, diabetes, gastroenterology, and hepatology since its inception in 2001. With an impressive Q1 ranking in multiple categories, including Endocrinology and Gastroenterology, Pancreatology stands out as a critical platform for disseminating peer-reviewed research that contributes to the evolving understanding of pancreatic diseases and associated metabolic disorders. This journal has gained significant recognition in the academic community, underscored by its robust Scopus rankings, positioning it favorably among its peers. While it currently does not offer open access, Pancreatology remains committed to advancing knowledge through high-quality publications and fostering innovation in clinical practice and research. Researchers, professionals, and students are invited to engage with the cutting-edge findings within its pages, which are essential for driving progress in this essential area of medicine.

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.